# Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Source: https://onco.cc/trials/nct02899052/  
OnCo record `nct02899052` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carfilzomib, Venetoclax, Dexamethasone in multiple myeloma, run by AbbVie, active and no longer recruiting.

## Summary

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) is a phase 2 interventional study registered as NCT02899052 by AbbVie, with 120 participants planned, started 2017-01-19 and due to reach its primary completion in 2027-06. Interventions recorded: Carfilzomib, Venetoclax, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02899052
- Phase: 2
- Setting: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Sponsor: AbbVie
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT02899052: https://clinicaltrials.gov/study/NCT02899052

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct02899052.json